## Effects of gender, age and menopausal status on serum apolipoprotein concentrations

Panagiotis Anagnostis<sup>1,2</sup>, John C. Stevenson<sup>3</sup>, David Crook<sup>4</sup>, Desmond G. Johnston<sup>1</sup>, Ian F. Godsland<sup>1</sup>

<sup>1</sup>Diabetes Endocrinology and Metabolic Medicine, Faculty of Medicine, Imperial College London, St. Mary's Campus, London, UK <sup>2</sup> Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Medical School Aristotle University of Thessaloniki, Thessaloniki, Greece

<sup>3</sup>National Heart and Lung Institute, Imperial College London, Royal Brompton Campus, UK.

<sup>4</sup>Clinical Investigations and Research Unit, Royal Sussex County Hospital, Sussex, UK.

**Introduction:** Inconsistent data exist as to whether menopause is associated with increased cardiovascular disease (CVD) risk. few studies have evaluated However, differences in apolipoprotein metabolism

Results: 109 pre-menopausal women (aged  $32.9 \pm 5.4$  years), 253 post-menopausal women (aged  $57 \pm 6.5$  years) and 307 men (aged  $52.4 \pm 10.5$  years) were included in the analysis. > Overall, apoB concentrations were highest in men but rose with age and menopause in women to converge with

according to menopausal status and gender. The aim of this study was to investigate the effects of gender and menopause on serum apolipoprotein B (apoB), A-I (apoA-I) and A-II (apoA-II) concentrations.

Methods: A cross-sectional analysis was undertaken of age and gender-related differences in apparently healthy Caucasian premenopausal and postmenopausal women not taking oral contraceptives or hormone replacement, Caucasian and men. Measurements included serum apoA-I, apoA-II, apoB, total cholesterol, low-density and high-density lipoprotein cholesterol (LDL-C and HDL-C respectively), triglycerides, cholesterol in HDL subfractions 2 and 3 and the apoB/apoA-I, LDL-C/apoB, HDL-C/apoA-I and HDL-C/apoA-II ratios. Analyses were undertaken with and without standardization for confounding characteristics and in 5 year age ranges.

concentrations in men in the age range 50-55 years.

- > The LDL-C/apoB ratio was generally higher in women than men, especially postmenopausally.
- Both apoA-I and apoA-II concentrations were highest in postmenopausal women and lowest in men.
- Men generally had the lowest ratios of HDL-C to apoA-I and to apoA-II, but the highest ratios were apparent in premenopausal women. I
- In multivariable analyses, incorporating age, BMI, smoking, alcohol, exercise and number of pregnancies, the above differences were sustained.

Table 2: Lipid–related variables - standa	ardized analysis					
	Group 1 1987-1991 Premenopausal women (n=109)	Group 2 1994-1998 Postmenopausal women (n=252)	Group 3 1992-1998 Men (n=307)	p Group 2 v Group 1	p Group 3 v Group 1	p Group 3 v Group 2
polipoprotein B (mg/dL)	67.0 (62.1, 74.2)	72.4 (63.2, 83.9)	74.6 (63.8, 87.0)	0.002	<0.001	0.1
polipoprotein A-I (mg/dL)	134 (124, 144)	144 (130, 158)	119 (108, 132)	<0.001	<0.001	<0.001
polipoprotein A-II (mg/dL)	32.9 (30.5, 35.7)	40.3 (37.5, 44.5)	36.5 (33.0, 40.1)	<0.001	<0.001	<0.001
poB / apoA-I	0.50 (0.45, 0.56)	0.50 (0.41, 0.61)	0.64 (0.53, 0.76)	0.9	<0.001	<0.001
LDL-C / apoB x 10 <sup>2</sup>	4.88 (4.61, 5.13)	4.78 (4.40, 5.18)	4.46 (4.06, 4.79	0.1	<0.001	<0.001
HDL-C / apoA-I x 10 <sup>2</sup>	1.26 (1.20, 1.34)	1.11 (1.02, 1.23)	1.12 (1.04, 1.22)	<0.001	<0.001	0.7
HDL-C / apoA-II x 10 <sup>2</sup>	5.37 (4.78, 5.80)	4.03 (3.43, 4.59)	3.63 (3.27, 4.13)	<0.001	<0.001	<0.001
otal cholesterol (mmol/L)	5.16 (4.74, 5.46)	5.63 (5.11, 6.29)	5.29 (4.69, 5.94)	<0.001	0.1	<0.001
riglycerides (mmol/L)	0.41 (0.28, 0.56)	0.92 (0.72, 1.28)	1.12 (0.75, 1.67)	<0.001	<0.001	<0.001
alculated LDL cholesterol (mmol/L)	3.15 (2.93, 3.50)	3.51 (2.98, 4.07)	3.32 (2.74, 3.86)	<0.001	0.1	0.006
HDL cholesterol (mmol/L)	1.71 (1.53, 1.88)	1.61 (1.39, 1.88)	1.33 (1.17, 1.56)	0.01	<0.001	<0.001
HDL <sub>2</sub> cholesterol (mmol/L)	0.76 (0.64, 0.96)	0.73 (0.58, 0.96)	0.57 (0.45, 0.72)	0.3	<0.001	<0.001
HDL <sub>3</sub> cholesterol (mmol/L)	0.93 (0.85, 0.99)	0.87 (0.77, 0.99)	0.77 (0.67, 0.86)	0.001	<0.001	<0.001
holesterol/HDL cholesterol	3.01 (2.77, 3.29)	3.48 (3.01, 4.15)	3.92 (3.31, 4.79)	<0.001	<0.001	<0.001
non-HDL cholesterol (mmol/L)	3.40 (3.15, 3.69)	3.95 (3.45, 4.57)	3.91 (3.31, 4.57)	<0.001	< 0.001	0.3
holesterol/HDL cholesterol non-HDL cholesterol (mmol/L)	3.01 (2.77, 3.29) 3.40 (3.15, 3.69)	3.48 (3.01, 4.15) 3.95 (3.45, 4.57)	3.92 (3.31, 4.79) 3.91 (3.31, 4.57)	<0.001 <0.001	<0.001 <0.001	<0.001 0.3

Table 1: Group characteristics						
	Group 1 1987-1991	Group 2 1994-1998	Group 3 1992-1998	p Group 2 v	p Group 3	p Group 3 v
	Premenopausal	Postmenopausal	Men	Group 1	v Group	Group 2
	women (n=109)	women (n=252)	(n=307)	-0.001	1	~0.001
age (years)	52.9 (5.4)	37.0 (0.3) 34.3 (2.0)	32.4 (10.3)	< 0.001	< 0.001	< 0.001
BMI (kg/m <sup>-</sup> )	21.0 (1.9)	24.5 (5.0)	20.2 (2.9)	< 0.001	<0.001	<0.001
number of pregnancies	0.3 (1.0)	1.7 (1.0)	-	<0.001	- 0.01	-
smoking	02 (76)	166 (02)	367 (00)	~0.001	0.01	0.04
rvone	63 (70) 19 (17)	100 (95)	207 (88)			
~15/day	2 (7)	1 (1)	20 (0) 10 (4)			
alcohol	o (/)	1 (1)	12 (4)	<0.001	<0.001	<0.001
None	4 (4)	138 (55)	26 (8)	0.001	0.001	V.VV1
<28 units/week	101 (92)	115 (45)	226 (74)			
>28 units/week	4 (4)	0(0)	55 (18)			
exercise		* (*/	()	<0.001	<0.001	0.001
None	50 (46)	146 (58)	136 (44)			
non-aerobic	49 (45)	41 (16)	47 (16)			
Aerobic	10 (9)	66 (26)	124 (40)			
apolipoprotein B (mg/dL)	55 (47, 62)	77 (65, 88)	76 (66, 90)	<0.001	<0.001	0.5
apolipoprotein A-I (mg/dL)	133 (119, 142)	144 (126, 158)	121 (110, 139)	<0.001	<0.001	<0.001
apolipoprotein A-II (mg/dL)	36 (33, 38)	41 (37, 45)	39 (36, 43)	<0.001	<0.001	<0.001
apoB / apoA-I	0.41 (0.35, 0.49)	0.53 (0.43, 0.64)	0.63 (0.52, 0.75)	<0.001	<0.001	<0.001
LDL-C / apoB x 10 <sup>2</sup>	4.31 (4.00, 4.62)	4.59 (4.13, 4.99)	4.36 (4.00, 4.79)	<0.001	0.1	< 0.001
HDL-C / apoA-I x 10 <sup>2</sup>	1.25 (1.17, 1.33)	1.10 (1.01, 1.24)	1.06 (0.97, 1.16)	<0.001	<0.001	< 0.001
HDL-C / apoA-II x 10 <sup>2</sup>	4.78 (4.11, 5.31)	3.80 (3.29, 4.56)	3.24 (2.83, 3.82)	<0.001	<0.001	<0.001
total cholesterol (mmol/L)	4.35 (4.01, 4.77)	5.64 (5.07, 6.29)	5.41 (4.77, 6.0	7) <0.001	<0.001	0.002
triglycerides (mmol/L)	0.57 (0.43, 0.75)	1.06 (0.83, 1.41)	1.27 (0.86, 1.9	4) <0.001	<0.001	< 0.001
calculated LDL cholesterol (mmol/L)	2.35 (1.95, 2.69)	3.47 (2.94, 4.11)	3.34 (2.80, 3.9	4) <0.001	< 0.001	0.1
HDL cholesterol (mmol/L)	1.66 (1.53, 1.84)	1.60 (1.33, 1.87)	1.30 (1.11, 1.5	3) 0.07	<0.001	< 0.001
HDL <sub>2</sub> cholesterol (mmol/L)	0.73 (0.57, 0.91)	0.64 (0.48, 0.89)	0.45 (0.31, 0.6	4) 0.1	<0.001	<0.001
HDL3 cholesterol (mmol/L)	0.93 (0.88, 1.01)	0.91 (0.79, 1.03)	0.83 (0.72, 0.9	2) <0.001	<0.001	< 0.001
cholesterol/HDL cholesterol	2.56 (2.28, 2.97)	3.50 (2.91, 4.24)	4.13 (3.31, 5.0	6) <0.001	< 0.001	< 0.001
non-HDL cholesterol (mmol/L)	2.64 (2.25, 3.06)	4.01 (3.40, 4.61)	3.99 (3.37, 4.7	9) <0.001	< 0.001	0.7

group. Significances: Kruskall-Wallis ANOVA all returned p<0.001 for significant variation between the three groups. Post-hoc, between-group comparisons were







## **References:**

Conclusions: Adverse effects of ageing in women, male gender and menopause on apoB concentrations and of menopause and, in particular, male gender on the cholesterol content of HDL particles were consistent with adverse effects on CVD risk, with male gender having the greatest effect.

Anagnostis P, et al. Maturitas 2015;81: 62-8, Godsland IF, et al. J Clin Endocrinol Metab. 1992;74:64-70, Godsland IF, et al. Clin Endocrinol (Oxf). 2004;60:541-549 Bittner V. Am Coll Cardiol. 2009;54:2374-2375.



Cardiovascular Endocrinology and Lipid Metabolism

Panagiotis Anagnostis





